Efficacy Clinical Trial
Official title:
The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma concentrations of imipenem, meropenem, amoxicillin, flucloxacillin, piperacillin, ceftazidime and cefepime in patients at increased risk of serious bacterial infections and currently understudied pharmacokinetics (the critically ill, the elderly, and the immunosuppressed). This prospective observational study will include adult patients with suspected or confirmed systemic bacterial infection receiving one of the above-named antibiotics and hospitalized in intensive-care, step-down, or hematology-oncology units of the Geneva University Hospitals (HUG). Eligible patients will be identified via the electronic health record (EHR). Patients receiving traditional intermittent dosing or prolonged infusions will undergo TDM for at least one intermediate (mid-interval) and one trough level at 24 hours (-12 or +48 hours) after the therapy's start. Patients receiving continuous infusions will undergo TDM for at least one steady-state level. Clinical course will be observed for 30 days from the start of the study antibiotic (1st day of study antibiotic =day 1). The primary outcome is incidence of clinical toxicity through day 30 after start of study antibiotic (as stratified by BL trough concentration). Secondary outcomes are listed below.
Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma concentrations of imipenem, meropenem, amoxicillin, flucloxacillin, piperacillin, ceftazidime and cefepime in patients at increased risk of serious bacterial infections and currently understudied pharmacokinetics (the critically ill, the elderly, and the immunosuppressed). This prospective observational study will include adult patients with suspected or confirmed systemic bacterial infection receiving one of the above-named antibiotics and hospitalized in intensive-care, step-down, or hematology-oncology units of the Geneva University Hospitals (HUG). Eligible patients will be identified via the electronic health record (EHR). Patients receiving traditional intermittent dosing or prolonged infusions will undergo TDM for at least one intermediate (mid-interval) and one trough level at 24 hours (-12 or +48 hours) after the therapy's start. Patients receiving continuous infusions will undergo TDM for at least one steady-state level. Clinical course will be observed for 30 days from the start of the study antibiotic (1st day of study antibiotic =day 1). The primary outcome is incidence of clinical toxicity through day 30 after start of study antibiotic (as stratified by BL trough concentration). Secondary outcomes are listed below. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00944268 -
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
|
Phase 3 | |
Completed |
NCT00504192 -
A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
Completed |
NCT05427305 -
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
Recruiting |
NCT06284746 -
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT04260113 -
Apatinib for Inoperable Advanced Chondrosarcoma
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04002440 -
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
|
N/A | |
Recruiting |
NCT02693587 -
Misodel or Angusta for Induction of Labour?
|
N/A | |
Completed |
NCT01194453 -
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT06205758 -
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
|
||
Recruiting |
NCT06122454 -
A Phase Ic/IIb Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HST in Patients With CHB
|
Phase 1/Phase 2 | |
Recruiting |
NCT05913271 -
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
|
||
Recruiting |
NCT05999656 -
Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot
|
N/A | |
Recruiting |
NCT05731258 -
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
|
||
Recruiting |
NCT03908138 -
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
|
Phase 4 | |
Completed |
NCT05648799 -
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) in Healthy Volunteers and Outpatients With COVID-19
|
N/A | |
Recruiting |
NCT03377933 -
The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection
|
N/A |